Profile of patients with psoriasis associated with hepatitis C virus infection

Journal of Dermatology

Volumn 40, Issue 6, 2013, Pages 428-433

  Imafuku, Shinichi ^a   Nakayama, Juichiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

epidemiology; hepatitis C; interferon ; psoriasis; tumor necrosis factor

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS C ANTIBODY; INTERFERON; PSORALEN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; PATHOGENESIS; PSORIASIS; SEX DIFFERENCE; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C; HUMANS; INTERFERONS; MALE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES;

EID: 84878604671     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12112     Document Type: Article

References (34)

1. Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H,. Prevalence of obesity/adiposity in Japanese psoriasis patients: adiposity is correlated with the severity of psoriasis. J Dermatol Sci 2009; 55: 74-76.
2. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK,. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol 2011; 147: 419-424.
3. Rosa DJ, Machado RF, Matias FA, et al,. Influence of severity of the cutaneous manifestations and age on the prevalence of several cardiovascular risk factors in patients with psoriasis. J Eur Acad Dermatol Venereol 2011; 26: 348-353.
4. Ide T, Hino T, Ogata K, et al,. A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C. Am J Gastroenterol 2009; 104: 70-75.
5. Kanazawa K, Aikawa T, Tsuda F, Okamoto H,. Hepatitis C virus infection in patients with psoriasis. Arch Dermatol 1996; 132: 1391-1392.
6. Chouela E, Abeldano A, Panetta J, et al,. Hepatitis C virus antibody (anti-HCV): prevalence in psoriasis. Int J Dermatol 1996; 35: 797-799.
7. Taglione E, Vatteroni ML, Martini P, et al,. Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. J Rheumatol 1999; 26: 370-372.
8. Yamamoto T, Yokozeki H, Nishioka K,. Evaluation of psoriatic patients with HCV infection. J Dermatol 2005; 32: 769-770.
9. Imafuku S, Nakayama J,. Questionnaire-based survey of the treatment of patients with psoriasis and hepatitis C in Japan. J Eur Acad Dermatol Venereol 2010; 24: 1114-1116.
10. Gota C, Calabrese L,. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 2003; 36: 511-518.
11. Kawada A, Tezuka T, Nakamizo Y, et al,. A survey of psoriasis patients in Japan from 1982 to 2001. J Dermatol Sci 2003; 31: 59-64.
12. Takahashi H, Nakamura K, Kaneko F, Nakagawa H, Iizuka H,. Analysis of psoriasis patients registered with the Japanese Society for Psoriasis Research from 2002-2008. J Dermatol 2011; 38: 1125-1129.
13. Tanaka J, Kumagai J, Katayama K, et al,. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology 2004; 47: 32-40.
14. Tanaka J, Kumada H, Ikeda K, et al,. Natural histories of hepatitis C virus infection in men and women simulated by the Markov model. J Med Virol 2003; 70: 378-386.
15. Tanaka J, Katayama K,. [Hepatitis C virus infection in Japan-epidemiology]. Nihon Rinsho 2011; 69 (Suppl 4): 15-22.
16. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL,. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-599.
17. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A,. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000; 75: 355-359.
18. Knobler H, Schattner A,. TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad. QJM 2005; 98: 1-6.
19. Eslam M, Khattab MA, Harrison SA,. Insulin resistance and hepatitis C: an evolving story. Gut 2011; 60: 1139-1151.
20. Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A,. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol 2003; 98: 2751-2756.
21. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N,. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003; 38: 1384-1392.
22. Zein NN,. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42: 315-322.
23. Abuabara K, Lee H, Kimball AB,. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: A cohort study. Br J Dermatol 2011; 165: 1066-1073.
24. Spah F,. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 2008; 159 (Suppl 2): 10-17.
25. Lang CH, Dobrescu C, Bagby GJ,. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992; 130: 43-52.
26. Hotamisligil GS, Shargill NS, Spiegelman BM,. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
27. Greenberg AS, McDaniel ML,. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002; 32 (Suppl 3): 24-34.
28. Ruan H, Lodish HF,. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 2003; 14: 447-455.
29. Brunasso AM, Puntoni M, Gulia A, Massone C,. Safety of anti-tumor necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford) 2011; 50: 1700-11.
30. Nestle FO, Conrad C, Tun-Kyi A, et al,. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135-143.
31. Lande R, Gregorio J, Facchinetti V, et al,. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449: 564-569.
32. Chandran V, Raychaudhuri SP,. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010; 34: J314-321.
33. Gudjonsson JE, Elder JT,. Psoriasis: epidemiology. Clin Dermatol 2007; 25: 535-546.
34. Tsai TF, Wang TS, Hung ST, et al,. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011; 63: 40-46.